Kyntra Bio (NASDAQ:KYNB) Stock Rating Raised to Hold at Zacks Research

Kyntra Bio (NASDAQ:KYNB) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks reports.

KYNB has been the topic of a number of other research reports. Weiss Ratings lowered Kyntra Bio from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday. Maxim Group started coverage on shares of Kyntra Bio in a report on Tuesday, October 13th. They issued a “buy” rating and a $35.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $43.00 price target on shares of Kyntra Bio in a report on Tuesday, September 1st. Finally, Lake Street Capital assumed coverage on shares of Kyntra Bio in a report on Thursday, September 17th. They set a “buy” rating and a $41.00 price target for the company. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $36.80.

Kyntra Bio Stock Performance

Shares of KYNB stock opened at $3.68 on Tuesday. The stock’s 50-day moving average is $6.04 and its two-hundred day moving average is $6.92. The firm has a market cap of $14.90 million, a price-to-earnings ratio of 0.08 and a beta of 1.08. Kyntra Bio has a 1 year low of $3.50 and a 1 year high of $10.47.

Institutional Trading of Kyntra Bio

An institutional investor recently bought a new stake in Kyntra Bio stock. ADAR1 Capital Management LLC acquired a new position in shares of Kyntra Bio Inc (NASDAQ:KYNB) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned approximately 0.26% of Kyntra Bio at the end of the most recent quarter. 72.71% of the stock is owned by institutional investors and hedge funds.

Kyntra Bio Company Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.